Tagrisso

Tagrisso is described in the supplied evidence as a pharmaceutical product. Its official website presents information organized around EGFR+ NSCLC across early-stage disease after surgery, locally advanced unresectable (stage 3) disease, and late-stage disease, and includes sections on clinical trial results, dosing, safety considerations, and support resources.

1. 1Treatment for Certain Types of EGFR+ NSCLC | TAGRISSOtagrisso.com
2. 2Treatment for Early-Stage EGFR+ NSCLC | TAGRISSOtagrisso.com
3. 3Late-Stage EGFR+ NSCLC | About TAGRISSO®tagrisso.com
4. 4Targeted Therapies for EGFR+ NSCLC | TAGRISSOtagrisso.com
5. 5Tagrissowikidata.org
6. 6FDA approves Tagrisso as adjuvant therapy for NSCLC subsethealio.com